Gyre Therapeutics, Inc.
GYRE
$6.13
$0.081.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -39.46% | 21.70% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -39.46% | 21.70% | |||
| Cost of Revenue | -29.60% | 7.06% | |||
| Gross Profit | -39.94% | 22.52% | |||
| SG&A Expenses | -30.02% | 55.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.91% | 56.84% | |||
| Operating Income | -5,768.33% | -98.27% | |||
| Income Before Tax | -13,895.45% | -100.87% | |||
| Income Tax Expenses | -52.23% | -23.21% | |||
| Earnings from Continuing Operations | -621.67% | -123.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 426.89% | 84.65% | |||
| Net Income | -404.41% | -147.73% | |||
| EBIT | -5,768.33% | -98.27% | |||
| EBITDA | -852.15% | -89.24% | |||
| EPS Basic | -403.70% | -147.61% | |||
| Normalized Basic EPS | -236.73% | -136.43% | |||
| EPS Diluted | -340.83% | -162.46% | |||
| Normalized Diluted EPS | -236.73% | -141.70% | |||
| Average Basic Shares Outstanding | 0.18% | 0.34% | |||
| Average Diluted Shares Outstanding | 0.21% | -12.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||